Download presentation
Presentation is loading. Please wait.
Published by정비 증 Modified over 6 years ago
1
Inhibition of NAMPT using the potent inhibitor FK866 sensitizes additional tumour cells to olaparib.A‐E.Sensitivity of the cell lines MDAMB468 (A), SUM149 (B), MDAMB231 (C), HS578T (D) and BT20 (E) was assessed as in Fig 3.F.Inhibition of NAMPT using the potent inhibitor FK866 sensitizes DLD1 BRCA2−/− tumour cells to olaparib. Inhibition of NAMPT using the potent inhibitor FK866 sensitizes additional tumour cells to olaparib.A‐E.Sensitivity of the cell lines MDAMB468 (A), SUM149 (B), MDAMB231 (C), HS578T (D) and BT20 (E) was assessed as in Fig 3.F.Inhibition of NAMPT using the potent inhibitor FK866 sensitizes DLD1 BRCA2−/− tumour cells to olaparib. Viability was measured after 14 days of continuous exposure to FK866/olaparib. Error bars represent the SEM from three independent experiments. ANOVA analysis tables are shown in Supporting Information Table S4. Ilirjana Bajrami et al. EMBO Mol Med. 2012;4: © as stated in the article, figure or figure legend
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.